Related Experiment Videos
The myeloperoxidase gene in Alzheimer's disease: a case-control study and meta-analysis
Onofre Combarros1, Jon Infante, Javier Llorca
1Service of Neurology, University Hospital Marqués de Valdecilla, University of Cantabria, 39008 Santander, Spain. combarro@unican.es
Abstract:
Myeloperoxidase (MPO) presence has been demonstrated in microglia associated with senile plaques, and contributes to Alzheimer's disease (AD) pathology through oxidation-induced damage. Recently, a functional biallelic (G/A) polymorphism in the promotor region (-463) of the MPO gene has been associated with susceptibility to AD, but the reports of this association have been inconsistent. A case-control study utilizing a clinically well-defined group of 315 sporadic AD patients and 327 control subjects was performed to test this association. The current study does not demonstrate any significant difference in MPO genotype or allele frequencies between AD patients and controls. A meta-analysis of all studies available gave a non-significant (P=0.83) odds ratio of 1.02 for the MPO GG genotype. Our study in the Spanish population as well as the meta-analysis argue against the hypothesis that the MPO gene is causally related to AD.
Insights
This study investigated the myeloperoxidase (MPO) gene polymorphism and Alzheimer's disease (AD) risk. Findings suggest the MPO gene is not causally linked to AD susceptibility.
Area of Science:
- Neuroscience
- Genetics
- Pathology
Background:
- Myeloperoxidase (MPO) is implicated in Alzheimer's disease (AD) pathology via oxidative damage.
- A specific MPO gene promoter polymorphism (-463 G/A) has been inconsistently linked to AD susceptibility.
Purpose of the Study:
- To investigate the association between the MPO -463 G/A polymorphism and sporadic AD in a Spanish population.
- To perform a meta-analysis to consolidate existing evidence on this genetic association.
Main Methods:
- A case-control study was conducted with 315 AD patients and 327 controls.
- Genotype and allele frequencies of the MPO -463 G/A polymorphism were analyzed.
- A meta-analysis of available studies was performed.
Main Results:
- No significant difference in MPO genotype or allele frequencies was found between AD patients and controls in the Spanish cohort.
- The meta-analysis yielded a non-significant odds ratio (1.02) for the MPO GG genotype (P=0.83).
Conclusions:
- The MPO -463 G/A polymorphism is not significantly associated with Alzheimer's disease risk.
- Current evidence, including this study and meta-analysis, does not support a causal relationship between the MPO gene and AD.